Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Karen H. Antman, MD, will receive the Distinguished Service Award for Scientific Leadership from ASCO at their annual meeting in Chicago. She is recognized for her development of a standard treatment regimen for sarcoma and has made significant contributions to cancer research.
Researchers found DNA abnormalities in the KIT gene linked to highly malignant skin cancers, offering hope for effective treatments. The study could lead to targeted therapies within 18 months.
A randomized phase II study found a trend towards increased survival in patients with advanced pancreatic cancer treated with axitinib plus gemcitabine compared to gemcitabine alone. The median overall survival was longer in the axitinib group, but the finding requires further investigation in a phase III trial.
Researchers at UT Southwestern Medical Center have developed a technique called bioluminescence imaging (BLI) to track the effectiveness of anti-cancer drugs. The technique involves adding luciferin to the bloodstream, which is carried to cells that have been altered to carry the firefly gene, causing them to emit light.
USC researchers have identified specific genetic markers in cancer cells that predict the benefit of a novel cancer drug. The study suggests that patients with tumors exhibiting these gene expression profiles may experience increased patient benefit from the incorporation of the drug into their treatment.
Women who have taken menopausal hormone therapy before are at a 37% higher risk of breast cancer than those who never used it. The risk is highest when taking combined estrogen and progestin therapies, with an increased risk by 73% during use.
Researchers at the University of Pennsylvania School of Medicine have identified a fruit fly protein called Argos that acts as a decoy receptor to neutralize tumor growth factors. This discovery may lead to new cancer drug designs by mimicking the silent binding of growth factors, similar to existing treatments like Avastin.
Long-term cancer survivors are experiencing unmet needs for symptom management, leading to a poor quality of life. The European CanCer Organisation is working to bridge the gap between oncology and palliative care to provide comprehensive care for all stages of disease.
A University of Rochester team has identified approximately 100 genes that cooperate to cause malignant cell transformation, providing a potential roadmap for next-generation cancer therapies. These genes, known as CRGs, encode proteins that regulate cell signaling and metabolism.
An experimental drug, OSU-HDAC42, has blocked prostate cancer progression in mice with an aggressive form of the disease. The agent reactivates genes that normally protect against cancer, shifting tumor progression to a more benign direction.
A US clinical trial confirms early use of targeted therapies like gefitinib can improve lung cancer patient outcomes. The study found that 31 out of 34 patients with sensitizing EGFR mutations showed significant tumor shrinkage or no growth after receiving Iressa treatment.
A study at Massachusetts General Hospital confirms the benefits of surgery for patients with persistent gastroesophageal reflux disease (GERD) symptoms. Most patients reported improved quality-of-life scores and high satisfaction rates with their long-term results, suggesting that antireflux surgery is an excellent treatment alternative.
A new study published in the Annals of Internal Medicine has found that sequential therapy is superior to standard treatment for eradicating H. pylori, with potential implications for future treatments. Additionally, the study reveals a higher risk of certain cancers among HIV-infected patients and suggests a possible association betwe...
Researchers at the University of Chicago Medical Center report positive results from a human trial of sorafenib, a cancer drug, as a treatment for pulmonary hypertension. Eight out of nine patients improved their exercise capacity and six experienced significant improvements in right ventricular ejection fraction.
Researchers found that NSAIDs can reduce adenoma burden by 64% and prevent advanced adenomatous polyp detection by 35%. Additionally, celecoxib has shown promise in preventing post-ERCP pancreatitis.
A Phase II clinical trial led by researchers at The University of Texas M. D. Anderson Cancer Center found that Iressa enhanced the effectiveness of hormonal therapy in treating specific types of metastatic breast cancer. The combination resulted in a 45% reduction in risk and improved clinical benefits for patients.
Researchers at WashU Medicine found that a bone-strengthening drug called zoledronic acid reduced the growth of breast tumor cells in bones by 23% after three months. Women treated with the drug were also less likely to develop large metastatic tumors, suggesting it may help prevent cancer spread.
A first-of-its-kind lung cancer chemoprevention trial found Celebrex reduces precancerous lesion proliferation and is safe for high-risk individuals. The study demonstrated the importance of COX-2 inhibition in preventing lung cancer, with potential implications for cancer prevention and treatment.
Childhood cancer survivors who received cyclophosphamide chemotherapy are at a higher risk of developing bladder cancer. Researchers found that the risk increases over time, with a significant increase after 20 years post-treatment.
A new study shows that an anesthetic injection into nerves in the neck can significantly reduce the frequency and severity of hot flashes and night awakenings in breast cancer survivors. The treatment, called a stellate ganglion block, was shown to provide lasting relief for most patients.
A pilot study found that stellate-ganglion block reduced hot flushes in breast cancer survivors by up to 90% and improved sleep quality. The procedure provided long-term relief with minimal side effects, increasing overall quality of life and compliance with treatment.
Researchers at University of Oklahoma discovered a chemical compound that prevents cancer in lab tests, successfully stopping normal cells from turning into cancer cells and inhibiting tumor growth. The compound, SHetA2, is being developed by NCI as a cancer prevention drug to be taken daily like a multi-vitamin.
A clinical trial evaluating sorafenib added to carboplatin/paclitaxel chemotherapy for lung cancer patients showed the combination offers no improved overall survival. Sorafenib results in worse outcomes for some patients with squamous histology.
Researchers have developed a test to accurately distinguish between squamous and non-squamous forms of non-small-cell lung cancer based on microRNA levels. This method can improve diagnosis and treatment guide for patients with the disease.
A study published in JAMA found that cisplatin is not an effective alternative to standard treatment for anal cancer, with a lower disease-free survival rate and more colostomies. The research suggests that fluorouracil plus mitomycin and radiotherapy remains the best treatment option for patients with anal canal cancer.
A randomized controlled trial found that chemotherapy with cisplatin before concurrent chemoradiation did not improve disease-free survival for patients with anal canal cancer. The therapy resulted in a higher rate of colostomy procedures and was associated with severe hematologic toxicity.
Researchers detail chemotherapy's damage to the brain, finding that healthy cells die off long after treatment ends. The study identifies 5-fluorouracil as a contributor to chemo brain, with damaged oligodendrocytes leading to cognitive decline and demyelination.
A new chemotherapy combination of docetaxel and capecitabine showed no improved efficacy in early breast cancer treatment, but increased non-haematological toxicities. The study found that the addition of capecitabine produced more side effects, such as hand-foot syndrome and diarrhoea.
A phase 1 clinical trial showed AME-133v had a potent tumor-halting response in patients with follicular lymphoma. The drug triggered signaling pathways within cells to slow or stop cancer growth, while causing minimal side effects.
OHSU Cancer Institute researchers discovered the gene ASPP2 is necessary in eliminating cancer cells. This protein activates pathways that tell cancer cells to die, protecting them from one of the steps leading to cancer. The study may lead to better therapies and cancer care for patients.
A new clinical trial has shown promising results with riluzole, a U.S. FDA-approved drug, slowing the growth of late-stage melanoma in human patients. The Phase 0 trial found three solid positive responses in nine patients, indicating potential as an adjunct to surgical treatment for stage 3 or 4 melanoma.
Researchers at UAB have discovered that triphendiol induces cell death in pancreatic and bile duct cancer cells, slowing tumor growth and sensitizing tumors to chemotherapy treatments. The investigational drug has shown promise as a potential treatment for pancreatic adenocarcinoma.
A new global alliance for pharmacogenomics is launching, aiming to identify genetic factors contributing to individual responses to medicines. Initial projects will focus on understanding breast cancer treatment effectiveness, pancreatic cancer side effects, and drug-induced heart rhythm disorders.
Researchers at Rutgers University have discovered that combining Celebrex and Lipitor can stop the transition of early prostate cancer to its more aggressive stage. This breakthrough could lead to a new treatment strategy for men with early-stage disease, potentially preventing cancer progression and saving lives.
Researchers at Thomas Jefferson University have found that common blood pressure medications can inhibit pancreatic cancer cell growth and cause cell death. The study suggests that these drugs may be part of a novel strategy to control the growth and spread of cancer.
Scientists at Georgetown University Medical Center have identified a small molecule that can block the action of the EWS-FLI1 fusion protein responsible for Ewing's sarcoma. This breakthrough could lead to the development of a targeted therapy for this rare and aggressive cancer.
Researchers found that a tumor protein present in aggressive breast cancers correlates with poor prognosis and growth/spread of disease. GRB-7 protein is related to HER-2/Neu gene, influencing treatment response and potentially informing clinical predictions and new therapies.
The Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research supports early career scientists, while the International Collaboration award promotes global cooperation to accelerate progress against cancer. The awards aim to encourage innovative approaches to cancer prevention and treatment.
Researchers have found that two drugs can bind to receptor sites on some tumors in different places at the same time. This discovery implies the possibility of a new combination therapy targeting EGFR proteins, which are present on the surface of many types of cancer cells.
Scientists at Northwestern University successfully blocked the communication between inflammatory cells and prostate cancer cells, reducing their invasive activity. The findings suggest using existing anti-inflammatory drugs to control cancer spread and metastasis.
A new drug candidate, TG101348, has been developed to treat a rare class of blood diseases called myeloproliferative disorders (MPD). The drug, which targets the JAK2 protein that causes overproduction of red blood cells, shows promise in halting disease progression and reversing excessive production of red blood cells.
A simple and fast screening technique has been developed to identify promising synthetic molecules that mimic therapeutic antibodies and can treat cancer at a lower cost. The new method screened over 300,000 peptoids and isolated five candidates that showed promise in treating human tumors.
Researchers at Boston University School of Medicine have developed a clinicogenomic model to test for lung cancer with increased sensitivity and specificity. The model combines gene expression and clinical risk factors, offering improved accuracy in identifying patients who would benefit from further invasive testing.
Researchers at UC Irvine have discovered the key to controlling polyketide ring formation, enabling the creation of new drugs for cancer treatment and cholesterol reduction. This breakthrough could lead to significant advancements in pharmaceuticals, with potential applications in obesity treatment and stem cell research.
A new breed of targeted cancer drugs is attacking specific proteins in cancer cells, but also causes devastating dermatologic side effects. The Cancer Skin Care Program at Northwestern University provides specially formulated lotions and drugs to help patients preserve their dignity and quality of life.
Researchers found that NSAIDs up-regulate anti-metastatic genes such as SPARC and TIMP-2 in human lung cancer cells. The study reveals a novel mechanism by which NSAIDs inhibit tumor invasion and metastasis, potentially providing a new strategy for cancer treatment.
A new mathematical model could revolutionize how scientists study cellular signaling pathways, potentially leading to more effective treatments for cancer and other diseases. The model takes advantage of today's computing power to provide a superior tool for understanding the complex interactions between cell signals.
OHSU Cancer Institute researchers found that SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML) by inhibiting T315I mutant and most, but not all, other Gleevec-resistant mutants. The combination of SGX393 with Sprycel or Tasigna completely suppressed resistance in a pre-clinical study.
Researchers at Stanford University School of Medicine have identified two new proteins that make up the telomerase complex, providing new targets for cancer treatments. The discovery could lead to the development of drugs that block telomerase and slow or stop cancer cell growth.
Researchers at IUPUI have created the first 3-D image of how bleomycin targets and binds to DNA. This breakthrough study may lead to improved chemotherapy drugs for various cancers.
A new feedback control scheme can search for the most effective drug combinations to treat various conditions, including cancers and infections. The discovery holds promise for facilitating new clinical drug-cocktail trials and optimizing combination therapies while reducing side effects.
Researchers found that dopamine can block the growth of new blood vessels in cancer cells by binding to a specific receptor on endothelial progenitor cells. This could lead to a potential treatment for cancer patients, as it slows down cancer progression and reduces tumor growth.
Researchers have discovered that an enzyme called MMP-2 is necessary for ovarian cancer to attach itself to new sites, and that blocking its production can slow the spread of the disease. In a mouse study, early treatment with an MMP-2 inhibitor reduced tumor growth by 68% and nearly doubled survival time.
A new study has discovered that specific pre-existing IgE antibodies are the primary cause of severe allergic reactions to cancer drug cetuximab. The research found these antibodies were more prevalent in certain regions of the US, including Tennessee, Arkansas, and North Carolina, which have higher rates of anaphylactic reactions.
The American Association for Cancer Research (AACR) is honoring world-class cancer researchers for their significant contributions to the fight against cancer. The AACR Awards Program recognizes outstanding achievements in basic cancer research, clinical care, therapeutics, and prevention.
Treatment with letrozole initiated one to seven years after stopping tamoxifen therapy cuts the risk of breast cancer recurrence in half and metastasis by 60%. The chance that a new tumor develops in the unaffected breast is also significantly reduced. These findings suggest aromatase inhibition can still offer preventive benefits.
A new study has demonstrated a lower risk of cardiac toxicity with dose-dense chemotherapy in early-stage HER2-positive breast cancer patients. The regimen, which administers standard doses of chemotherapy agents more frequently, pairs safely with trastuzumab and resulted in only 1.4% cardiac events after 28 months of follow-up.
A novel brain cancer drug showed promising results in mice but caused permanent bone damage in younger animals. The study raises concerns about using similar drugs to treat children's cancers until further understanding of possible risks is gained.
A study found that efficient primary care can prevent over 50% of hospitalizations caused by diabetic ketoacidosis, digestive haemorrhage, and chronic bronchitis in older patients. Effective management of these conditions could also reduce the risk of hospitalization for other health problems.
A combination of two platelet inhibitors, aspirin and APT102, reduced bone tumors in laboratory mice with breast or melanoma cancer. The drugs work by blocking platelets' ability to clot and aid tumor cells, slowing down metastasis.